Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04869020 · ClinicalTrials.gov registry record · NA
Evaluation of the OtoBand in Subjects With Self-reported Vertigo to Reduce Severity of Vertigo in a Real-world Setting
A NA study of Vertigo, sponsored by Otolith Labs.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT04869020 is a NA study of Vertigo that has completed, run by Otolith Labs. The registered enrollment target is 40 participants, below the 16,106-participant average among 5 other Vertigo trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04869020, a NA study of Vertigo, has completed, sponsored by Otolith Labs.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This study seeks to gather data on the effect of a device, the OtoBand, in participants who have reported symptoms of vertigo, compared to the effect of using one of two sham devices. The study is designed to be conducted remotely using video conferencing between representatives of the manufacturer of the Otoband and participants. In order to comply with requirements for non-essential contact due to the Covid-19 pandemic there will be no person to person contact in the study.
Conditions Studied
Interventions
- DEVICE Otoband
- DEVICE Sham A
- DEVICE Sham B
Study Locations (1)
District of Columbia
- Otolith Labs - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2021-04-19 |
| Est. Completion | 2022-11-26 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04869020
The ClinicalTrials.gov registry entry for NCT04869020 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 16,106-participant average among 5 other Vertigo trials with a reported enrollment target (100% lower). The listed sponsor is Otolith Labs, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Vertigo appearing as the primary indexed condition, and to 3 interventions - of which Otoband is the first listed.
NCT04869020 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.
Frequently Asked Questions
What is clinical trial NCT04869020 about?
NCT04869020 is a clinical study titled "Evaluation of the OtoBand in Subjects With Self-reported Vertigo to Reduce Severity of Vertigo in a Real-world Setting". This study seeks to gather data on the effect of a device, the OtoBand, in participants who have reported symptoms of vertigo, compared to the effect of using one of two sham devices. The study is designed to be conducted remotely using video conferencing between representatives of the manufacturer ...
What is the current status of trial NCT04869020?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2021-04-19. Estimated completion is 2022-11-26.
What conditions does trial NCT04869020 study?
This clinical trial studies the following conditions: Vertigo.
What interventions are being tested in trial NCT04869020?
The interventions under investigation include: Otoband (DEVICE), Sham A (DEVICE), Sham B (DEVICE).
Who is sponsoring clinical trial NCT04869020?
This trial is sponsored by Otolith Labs, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04869020 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vertigo
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fall Risk Assessment and Speech Intelligibility Enhancement Using In-ear Device
RECRUITING · NA
-
Reducing Vertigo Associated With MRI Machines
RECRUITING · NA
-
Implementation of Evidence-Based Practice for Dizziness
ACTIVE NOT RECRUITING · NA
-
Gaze and Postural Stability in Multiple Sclerosis
COMPLETED · NA
-
Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.